Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0018133 (
graft-versus-host disease
)
18,032
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Despite contemporary typing procedures for bone marrow transplantation (BMT),
graft-versus-host disease
(
GVHD
) continues to be a major complication of transplants performed between MHC-matched donors and recipients. Although
GVHD
can be alleviated by T cell depletion, this procedure increases the risk of graft failure and leukemic relapse and therefore is not a solution to the
GVHD
problem. The high degree of variation in the intensity of
GVHD
observed in different patients suggests that multiple non-MHC genetic factors influence
GVHD
severity. We hypothesize that, in addition to minor histocompatibility antigen disparities, polymorphisms in genes encoding immunologic effector molecules may be important factors influencing
GVHD
development. This study aims to explore this hypothesis by identifying non-MHC genes that influence the outcome of BMT in a murine model. In this model, B10.D2 donor leukocytes cause acute
GVHD
in (C57BL/6xDBA/2)F1 (B6D2F1) recipients, whereas DBA/2 donor leukocytes do not. To date, a locus on chromosome 1 has been identified as influencing the severity of
GVHD
in this model. Our current study shows that a locus on chromosome 2 acts independently of the chromosome 1 locus to also influence
GVHD
severity in this model. The region of chromosome 2 implicated in our study contains genes encoding beta2-microglobulin, the minor histocompatibility antigen
H-3
and the pro-inflammatory cytokine IL-1.
...
PMID:A locus on chromosome 2 influences the development of acute graft-versus-host disease in a murine model. 1038 59